NOX-E36 (emapticap pegol) binds and neutralizes the human chemokine CCL2, also referred to as MCP-1 (C-C Chemokine Ligand 2 / Monocyte Chemoattractant Protein 1 and the related chemokines CCL8, CCL11 and CCL13). MCP-1/CCL2 is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. Both CCL2 and its receptor CCR2 have been demonstrated to be induced and involved in a variety of inflammatory diseases and are implicated in cancer spread and immune privilege of tumors.

NOX-E36 was originally developed in diabetic nephropathy where it completed a Phase 2a exploratory study which included 76 patients with Type 2 diabetes and proteinuria on top of standard of care.

Recent clinical studie available at

  • NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
    (ref: NCT01547897)
    Status: completed

Recent NOX-E36 press releases

NOX-E36 press release archive

NOX-E36 publication archive